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Abstracts / Biol Blood Marrow Transplant 19 (2013) S279eS312S308cycles) and one patient received decitabine 20mg/m2 intra-
venously for 5 days for 3 cycles. Median initial Azacitidine
dose of 50 mg/m2 (range, 25-75 mg/m2) were given at
a median of 40 days (range, 38-101 days) post HSCT
engraftment. Azacitidine doses were increased based on
counts to a maximum dose of 75mg/m2. With a median
follow-up of 24months (range, 1.7-49 months) 6 patients are
alive in complete remission. Twenty-four month progression
free survival is 51% with overall survival of 76%.
Conclusion: Given the dismal results of progression free
survival and overall survival following allogeneic HSCT in
high risk AML or non responsive MDS, hypomethylating
agents given post transplantation provide a valuable
approach to prolonging remission.398
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Engraftment among allogeneic HCT recipients is associ-
ated with endothelial damage, cytokine release and elevated
white count. The impact of persistent leukocytosis after
engraftment on survival and transplant related complica-
tions such as graft versus host disease is not well established.
In this study, we retrospectively reviewed the charts of 74
consecutive patients who underwent allogeneic HCT in
a single center between 2009 and 2011. Neutrophil engraft-
ment was deﬁned as an absolute neutrophil count of
0.5x103/ml for 3 consecutive days. Patients’ blood counts
were assessed for 60 days post engraftment (three times per
week). Persistent Leukocytosis (group A) was deﬁned as
a white blood cell count of >10 x103 /ml for more than four
different blood draws. Patients who had leukocytosis for
three or less blood draws were called group B. Conditioning
regimens included myeloablative MA (Fludarabine/Busulfan
or cytoxan/total body irradiation) and reduced intensity RIC
(ﬂudarabine/busulfan or ﬂudarabine/cytoxan/low dose TBI).
Graft versus host disease prophylaxis included metho-
trexate/tacrolimus for myeloablative and tacrolimus/Myco-
phenolate for reduced intensity conditioning.
The median age was 51 years (range: 18-74 years). Graft
source included matched related (n¼24), Unrelated donor(n¼48) and cord blood (n¼2). 36 patients received MA
conditioning and 37 had RIC conditioning. Median follow up
for the cohort was 556 days. Median time to neutrophil
engraftment was 13 days. 22 patients had persistent leuko-
cytosis (group A) during the ﬁrst 60 days post engraftment.
The two groups did not differ in terms of age, gender, diag-
nosis (acute leukemia versus other), disease risk and condi-
tioning regimen (table 1). Group A had a higher proportion of
related donor source (50% versus 31%; P ¼ .05). One year
overall survival was signiﬁcantly worse in group A (40.6%
versus 74.7%; P ¼ .009). Grade II-IV acute graft versus host
disease was higher among group A patients (68% versus 48%;
P ¼ .18) although not statistically signiﬁcant. The cause of
death among patients with persistent leukocytosis included
acute GVHD (n¼6), relapse (n¼5), infection (n¼2) and
thrombosis (n¼1).
In conclusion, Persistent leukocytosis post engraftment in
allo-HCT recipients is associated with worse overall survival
and may be an independent risk factor for acute GVHD.
Despite a larger proportion of related donors among the
leukocytosis group, our data showed a trend towards higher
incidence of acute GVHD. The exact mechanism leading to
prolonged leukocytosis is not clear and further studies to
conﬁrm the association between leukocytosis and clinical
outcomes are warranted.399
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The aim of this study was to determine the incidence,
clinical features and outcome of invasive fungal disease (IFD)
after either an unmanipulated haploidentical hematopoietic
stem cell transplantation (HSCT) or a human leukocyte
antigen (HLA)-matched sibling HSCT. This was a head-to-
head comparative study performed at a single center.
Patients were admitted between 2007 and 2010, and IFDwas
evaluated according to the revised EORTC/MSG criteria, with
only proven and probable cases included. Of the 1,042
consecutive patients enrolled, 390 received the HLA-
matched HSCT and 652 received an unmanipulated hap-
loidentical HSCT. A total of 61 (5.8%) patients had IFD, which
was broken down into 15 proven cases and 46 probable
cases. The median time of diagnosis was 35 days (range
6-405) after transplantation. Themost common involved site
was the lung (52/61), and Aspergillus was the most common
(18/29) pathogen. The incidence of IFD after an unmanipu-
lated haploidentical HSCT was signiﬁcantly higher than the
HLA-matched transplant (7.1% versus 3.3%, respectively,
P ¼ .007), which was caused by the more early IFD (before
day 40). IFD occurred later in patients receiving an HLA-
matched transplant compared to patients receiving the
unmanipulated haploidentical HSCT (141.5 versus 23 days,
respectively, P ¼ .04). The response to therapy and the
mortality rate corresponding to IFD were similar between
the two types of transplantation. In conclusion, patients
received an unmanipulated haploidentical HSCT had higher
risk of IFD than those patients received an HLA-matched
HSCT, but the prognosis of IFD was not associated with the
HLA type.
